Angiopep-conjugated nanoparticles for targeted long-term gene therapy of parkinson's disease

Pharmaceutical Research

Volumn 30, Issue 10, 2013, Pages 2549-2559

  Huang, Rongqin ^a   Ma, Haojun ^a   Guo, Yubo ^a   Liu, Shuhuan ^a   Kuang, Yuyang ^a   Shao, Kun ^a   Li, Jianfeng ^a   Liu, Yang ^a   Han, Liang ^a   Huang, Shixian ^a   An, Sai ^a   Ye, Liya ^b   Lou, Jinning ^b   Jiang, Chen ^a  

^a FUDAN UNIVERSITY   (China)

^b CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

Author keywords

angiopep conjugated nanoparticles; dendrigraft poly L lysine; gene therapy; multiple dosing administrations; Parkinson's disease

Indexed keywords

ANGIOPEP DENDIGRAFT POLYLYSINE POLYETHYLENE GLYCOL CONJUGATED NANOPARTICLE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL TRANSPORT; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; NEUROPROTECTION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PARKINSON DISEASE; PARTICLE SIZE; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; ZETA POTENTIAL;

ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; LDL-RECEPTOR RELATED PROTEINS; MALE; NANOCONJUGATES; PARKINSON DISEASE; PEPTIDES; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 84883889734     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1005-8     Document Type: Article

References (27)

1. Di Stefano A, Sozio P, Cerasa LS, Iannitelli A. L-Dopa prodrugs: an overview of trends for improving Parkinson's disease treatment. Curr Pharm Des. 2011;17(32):3482-93.
2. Reichmann H, Emre M. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone. Expert Rev Neurother. 2012;12(2):119-31.
3. Björklund A, Björklund T, Kirik D. Gene therapy for dopamine replacement in Parkinson's disease. Sci Transl Med. 2009;1(2):2ps2.
4. Huang RQ, Ke WL, Liu Y, Wu DD, Feng LY, Jiang C, et al. Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model. J Neurol Sci. 2010;290(1-2):123-30.
5. Boado RJ, Pardridge WM. The Trojan horse liposome technology for nonviral gene transfer across the blood-brain barrier. J Drug Deliv. 2011;2011:296151.
6. Wagner S, Zensi A, Wien SL, Tschickardt SE, Maier W, Vogel T, et al. Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood-brain barrier model. PLoS One. 2012;7(3):e32568.
7. Demeule M, Currie JC, Bertrand Y, Ché C, Nguyen T, Régina A, et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J Neurochem. 2008;106(4):1534-44.
8. Ke WL, Shao K, Huang RQ, Han L, Liu Y, Li JF, et al. Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials. 2009;30(36):6976-85.
9. Huang RQ, Liu SH, Shao K, Han L, Ke WL, Liu Y, et al. Evaluation and mechanism studies of PEGylated dendrigraft poly-L-lysines as novel gene delivery vectors. Nanotechnology. 2010;21(26):265101.
10. Huang RQ, Ke WL, Han L, Li JF, Liu SH, Jiang C. Targeted delivery of chlorotoxin-modified DNA-loaded nanoparticles to glioma via intravenous administration. Biomaterials. 2011;32(9):2399-406.
11. Xie Y, Ye LY, Zhang XB, Cui W, Lou JN, Nagai T, et al. Transport of nerve growth factor encapsulated into liposomes across the blood-brain barrier: In vitro and in vivo studies. J Control Release. 2005;105(1-2):106-19.
12. Canzoniero LM, Adornetto A, Secondo A, Magi S, Dell'aversano C, Scorziello A, et al. Involvement of the nitric oxide/protein kinase G pathway in polychlorinated biphenyl-induced cell death in SH-SY 5Y neuroblastoma cells. J Neurosci Res. 2006;84(3):692-7.
13. Huang RQ, Han L, Li JH, Ren FL, Ke WL, Jiang C, et al. Neuroprotection in a 6-OHDA-lesioned Parkinson model using Lactoferrin-modified Nanoparticles. J Gene Med. 2009;11(9):754-63.
14. Huang RQ, Ke WL, Liu Y, Jiang C, Pei YY. The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain. Biomaterials. 2008;29(2):238-46.
15. Spuch C, Navarro C. Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer's disease and Parkinson's disease). J Drug Deliv. 2011;2011:469679.
16. Shao K, Huang RQ, Li JF, Han L, Ye LY, Lou JN, et al. Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain. J Control Release. 2010;147(1):118-26.
17. Alam M, Schmidt WJ. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res. 2002;136(1):317-24.
18. Samantaray S, Knaryan VH, Guyton MK, Matzelle DD, Ray SK, Banik NL. The parkinsonian neurotoxin rotenone activates calpain and caspase-3 leading to motoneuron degeneration in spinal cord of Lewis rats. Neuroscience. 2007;146(2):741-55.
19. Hirsch EC, Höglinger G, Rousselet E, Breidert T, Parain K, Feger J, et al. Animal models of Parkinson's disease in rodents induced by toxins: an update. J Neural Transm Suppl. 2003;65:89-100.
20. Sherer TB, Betarbet R, Kim JH, Greenamyre JT. Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci Lett. 2003;341(2):87-90.
21. Mercanti G, Bazzu G, Giusti P. A 6-hydroxydopamine in vivo model of Parkinson's disease. Methods Mol Biol. 2012;846:355-64.
22. Li JF, Zhou L, Ye DY, Huang SX, Shao K, Huang RQ, et al. Choline-derivate-modified nanoparticles for brain-targeting gene delivery. Adv Mater. 2011;23(39):4516-20.
23. Liu SH, Guo YB, Huang RQ, Li JF, Huang SX, Kuang YY, et al. Gene and doxorubicin co-delivery system for targeting therapy of glioma. Biomaterials. 2012;33(19):4907-16.
24. Tsogas I, Theodossiou T, Sideratou Z, Paleos CM, Collet H, Rossi JC, et al. Interaction and transport of poly(L-lysine) dendrigrafts through liposomal and cellular membranes: the role of generation and surface functionalization. Biomacromolecules. 2007;8(10):3263-70.
25. Duarte EP, Curcio M, Canzoniero LM, Duarte CB. Neuroprotection by GDNF in the ischemic brain. Growth Factors. 2012;30(4):242-57.
26. Boger HA, Middaugh LD, Huang P, Zaman V, Smith AC, Hoffer BJ, et al. A partial GDNF depletion leads to earlier age-related deterioration of motor function and tyrosine hydroxylase expression in the substantia nigra. Exp Neurol. 2006;202(2):336-47.
27. Jiang C, Koyabu N, Yonemitsu Y, Shimazoe T, Watanabe S, Naito M, et al. In vivo delivery of glial cell-derived neurotrophic factor across the blood-brain barrier by gene transfer into brain capillary endothelial cells. Hum Gene Ther. 2003;14(12):1181-91.